Collaboration enables further expansion of mass cytometry in the Middle East
SOUTH SAN FRANCISCO, Calif., Feb. 17 10, 2022 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq: FLDM), a provider of innovative biotechnology tools whose vision is to improve lives through comprehensive health information, today announced a collaboration agreement with the Abu Dhabi Stem Cells Center (ADSCC) for the development of targeted stem cell therapies and research applications using two Fluidigm® mass cytometry and tissue imaging technologies: Imaging Mass Cytometry™ (IMC™) and Maxpar® Direct™ Immune Profiling Assay™.
ADSCC, founded in 2019, is a specialty healthcare center that focuses on cell therapy and regenerative medicine in addition to cutting-edge stem cell research. The Center collects, processes, characterizes and stores cellular products for clinical applications in regenerative medicine and hematopoietic transplantation.
The ADSCC collaboration with Fluidigm represents an opportunity to increase the visibility of mass cytometry technology to potential new customers in the Middle East and establish a base for expansion in the region.
“We seek the technologies that can most effectively provide meaningful insights as we work to develop new approaches to stem cell therapies, and Fluidigm’s IMC and immune profiling tools are exceptional in this regard,” said Dr. Yendry Ventura Carmenate, specialist in immunology, Director General of ADSCC. “We believe these tools will ultimately accelerate our global expertise in this progressive area of medicine and inform targeted therapies for our patients. »
BMI enables researchers to better understand the spatial environment of cells to answer important translational and clinical research questions related to disease. The Fluidigm Maxpar direct immune profiling test was the first complete sample-response solution for large-scale immune profiling of blood samples. Fluidigm’s immune profiling solution includes reagents, the CyTOF® mass cytometry system, and analytical tools to provide analysis of 37 immune cell populations.
As part of this collaboration, ADSCC will: gain early access to reagents and software being developed by Fluidigm; evaluate Fluidigm pre-released materials and products in development; participate in Fluidigm events and host visits or experiments from Fluidigm customers or prospects regarding the Helios™ system and the Hyperion™ imaging system, which use CyTOF technology; and participate in product development discussions regarding Helios and the Hyperion Imaging System.
“We are delighted that the Abu Dhabi Stem Cell Center has chosen imaging mass cytometry to support its mission to deliver effective and targeted treatments in cell therapies and regenerative medicine,” said Chris Linthwaite, President and chief Executive Officer. “In addition to increasing the visibility of CyTOF technology in the region, we believe this collaboration will provide opportunities for new products and workflows. For example, we are looking at the panels that ADSCC has developed for applications of stem cells in a number of pathologies with a view to potential commercialization.
“IMC is a leading tool for developing a more meaningful approach to precision medicine for better healthcare decision-making, and we are honored to partner with ADSCC to expand the use of our mass cytometry technology in the Middle East.
Some of Fluidigm’s key growth strategies include adopting technology in translational and clinical research, as well as accelerating development of consumables and assays through increased organic investments and partnerships. Globally, mass cytometry is used by nine of the top 10 pharmaceutical companies, and Fluidigm mass cytometry technology, including CyTOF, Imaging Mass Cytometry and Maxpar Direct, has been used in more than 180 clinical trials nationals.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the benefits of a collaboration agreement for the visibility and adoption of Fluidigm products and technologies and the potential benefits of research conducted using Fluidigm products and technologies. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from results currently anticipated, including, but not limited to, risks relating to interruptions or delays in the supply of components or materials for, or manufacture of Fluidigm products. ; potential product performance and quality issues; intellectual property risks; competetion; uncertainties in contractual relationships; and reductions in research and development expenditures or changes in budget priorities by customers. Information about these additional risks and uncertainties and other information affecting Fluidigm’s business and results of operations is contained in its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and its other filings. with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements, except as required by law.
Fluidigm (Nasdaq: FLDM) focuses on the most pressing translational and clinical research needs, including cancer, immunology and immunotherapy. Using proprietary CyTOF and microfluidic technologies, we develop, manufacture and market multi-omics solutions to gain meaningful insights into health and disease, identify biomarkers to inform decisions and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide.
With them, we strive to improve everyone’s quality of life. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, CyTOF, Direct, Helios, Hyperion, Imaging Mass Cytometry, IMC, Immune Profiling Assay and Maxpar are trademarks and/or registered trademarks of Fluidigm Corporation or its subsidiaries in the United States and/or other countries. All other trademarks are the exclusive property of their respective owners. Fluidigm products are intended for Use for research only. Not for use in diagnostic procedures.
About Abu Dhabi Stem Cell Center
Abu Dhabi Stem Cells Center is a specialist healthcare center focused on cell therapy and regenerative medicine, as well as cutting-edge stem cell research in the region. The center was founded in March 2019 to meet the growing national and regional demand for advanced medical services and treatments in the United Arab Emirates.
We use our website (fluidigm.com), investor website (investors.fluidigm.com), company Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm) and the LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels for the distribution of information about our products, our planned financial and other announcements, our participation in upcoming investor and industry conferences, and other matters. This information may be considered material information and we may use these channels to comply with our disclosure obligations under Regulation FD. Accordingly, investors should monitor our website and social media accounts in addition to monitoring our press releases, SEC filings, public conference calls and webcasts.
415 389 6400
650 243 6621